Changes in the cardiometabolic risk factors post elexacaftor-tezacaftor-ivacaftor therapy; a real-world prospective single center study. - Adult Cystic Fibrosis Conference, 2023

Treatment and management (1)

Chair(s): Pierre-Regis Burgel, Ruth Keogh

Session type: Oral presentation

Changes in the cardiometabolic risk factors post elexacaftor-tezacaftor-ivacaftor therapy; a real-world prospective single center study.

HISHAM I S IBRAHIM

EVENTS HOME

e-poster

Previous presentation

Next presentation

Session content

Changes in nutritional status and muscular strength in adult patients with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ETI)

Cecilia Brignole

Elexacaftor/Tezacaftor/Ivacaftor for adult cystic fibrosis patients with preserved lung function: a case series

Zisis Balmpouzis

e-poster

Side-effects and ETI-treatment: a multidisciplinary challenge

Nele Duplacie

e-poster

Assessing and improving patient knowledge gaps relating to the administration of elexacaftor/tezacaftor/ivacaftor in an adult cystic fibrosis clinic population

Joshua Sill

e-poster

Plasma concentrations of elexacaftor, tezacaftor and ivacaftor in adult people with cystic fibrosis: A pilot study

Adrienn Banki

e-poster

Changes in the cardiometabolic risk factors post elexacaftor-tezacaftor-ivacaftor therapy; a real-world prospective single center study.

Hisham I S Ibrahim

e-poster

A patient journey from lumacaftor/ivacaftor (LI) to tezacaftor/ivacaftor (TI) to elexacaftor/tezacaftor/ivacaftor (ETI): a single center case series

Noreen Tangney

e-poster

CDN Connection Issue

#{title}